

Annexon Presentations and Related References

Inhibition of C1q, initiator of the classical complement cascade, by ANX005 for the treatment of Guillain-Barre Syndrome: results from a Phase 1b study

2020 American Academy of Neurology (AAN) Annual Meeting

Annexon Biosciences

April 2020

[Annexon AAN-presentation-Phase-1b-GBS](#)

Leveraging Biomarkers to De-risk Clinical Development in Complement Mediated Diseases: Progress with Anti-C1q Inhibitor ANX005

4th Annual Conference on Complement Mediated Drug Development Summit

Annexon Biosciences

October 2020

[Annexon Complement-summit-presentation-October-2020](#)

The complement system: an unexpected role in synapse pruning during development and disease

Annual Review of Neurology

Stephan AH, Barres BA, and Stevens B

July 2012 35:369-389

The complement system mediates microglial dependent remodeling of spinal motor circuits in development and in Spinal Muscular Atrophy

Cell Reports

Vukojicic A, Delestree N, Fletcher EV et al.

December 2019 29:3087-3100 e3087

Brain specific proteins decline in cerebrospinal fluid of humans with Huntington's disease

Molecular & Cell Proteomics

Fang Q, Strong A, Law W et al.

Mar 2009 8:451-466

Evaluation of mutant huntington and neurofilament proteins as biomarkers in Huntington's disease

Science Translational Medicine

Gaiani A, Martinelli I, Bello L et al.

September 2018 DOI:
10.1126/scitranslmed.aat7108